12-Mar-2020: The global auto-injectors
market size is expected to reach USD 3.18 billion by
2026, according to a new report by Grand View Research, Inc, exhibiting a CAGR
of 19.5%. Rising incidence of anaphylactic shock and other diseases such as
diabetes, rheumatoid, & multiple sclerosis along with increasing approvals
of auto-injectors are impelling growth.
Increasing
prevalence of life-threatening allergies and rising demand for these devices
are expected to aid growth. As per the Food Allergy Research & Education, around
200, 000 people every year need emergency medical care for allergic food
reactions.
In addition,
increasing approvals are anticipated to drive growth. For instance, in August
2018, U.S. FDA approved the first generic epinephrine auto-injector of Teva
Pharmaceuticals to treat emergency allergic reactions, including anaphylaxis.
Generic versions of EpiPen Jr & EpiPen of 0.15 mg & 0.3 mg,
respectively, are indicated for pediatric and adult patients weighing more than
33 pounds.
Moreover,
manufacturers are also developing new products and innovative technologies,
which is expected to propel market growth. For instance, in June 2018, AbbVie
GK launched Humira, which is a fully human antitumor necrosis factor alpha
monoclonal antibody formulation with lock function & injection start &
end alerts as well as an inspection window and injects completely in 10
seconds. Demand for these devices is increasing as they are designed in
accordance with patient acceptance and compliance. Technological advancements
are anticipated to make them more convenient and user-friendly. This is
encouraging patients to adopt this technology for chronic illnesses.
In
depth research report on Auto-Injectors Market
Further key findings from the report suggest:
·
Disposable auto-injectors emerged as the largest segment
owing to convenience and ease of use
·
Homecare settings accounted for largest share in end-use
segment owing to increasing demand of products for daily administration of
insulin
·
North America dominated the auto-injectors market with
largest share in 2018. Increasing demand for new technologies along with
advanced healthcare infrastructure is expected to boost market growth during
the forecast period
·
Asia Pacific is expected to witness fastest growth during the
forecast period owing to increasing number of diabetic patients
·
Some of the key players are Eli Lilly; Scandinavian Health
Ltd.; AbbVie, Inc.; Amgen; Owen Mumford; Ypsomed; Teva Pharmaceutical; Biogen
Idec; Mylan N.V.; Pfizer, Inc.; and Sanofi
Grand View Research
has segmented the global auto-injectors market based on product type, disease
indication, end use, and region:
Auto-injectors Product Type Outlook (Revenue, USD Million,
2015 - 2026)
·
Disposable Auto-Injectors
·
Reusable Auto-Injectors
·
Prefilled Auto-Injectors
·
Empty Auto-Injectors
Auto-injectors Disease Indication Outlook (Revenue, USD
Million, 2015 - 2026)
·
Rheumatoid Arthritis
·
Multiple Sclerosis
·
Diabetes
·
Anaphylaxis
·
Other Therapies
Auto-injectors End-use Outlook (Revenue, USD Million, 2015 -
2026)
·
Homecare Settings
·
Hospitals & Clinics
·
Ambulatory Surgical Centers
Browse
more research reports of this category:
About
Grand View Research
Grand View Research, Inc. is the
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, the company offers market
intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and
energy.
No comments:
Post a Comment